Non-metastatic Castration-resistant Prostate CancerNCT06334120
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
An observational study of Non-metastatic Castration-resistant Prostate Cancer and Metastatic Hormone-sensitive Prostate Cancer, run by Bayer at 1 site in South Korea.
Trial summary
This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). Read more about this study
- Who is it for?
- Ages 19 years and older, men only
- Conditions the study is for
- Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer
- What is being tested?
- Darolutamide (Nubeqa, BAY1841788)
- How many people
- 600 participants
- Where
- 1 siteSouth Korea
- Study dates
- 25 Sep 2024to 30 Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.
Who may be able to join
- Male aged ≥19 years
- Patients with high risk nmCPRC
- Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL])
- PSA doubling time < 10 months
- Patients with mHSPC
- histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
Show all 9Show fewer
- be candidates for androgen-deprivation therapy with/without docetaxel.
- Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice
- Written informed consent from subject or legal representative; assent from subject when appropriate
Who cannot join
- Patients participating in an investigational program with interventions outside of routine clinical practice
- Participants with contraindication according to the locally approved prescribing information
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.
This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.
Read more
To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.
During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.
Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.
- Conditions
- Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer
- Being tested
- Darolutamide (Nubeqa, BAY1841788)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Darolutamide (Nubeqa, BAY1841788)Drug
The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
| Study group | Role | What they receive |
|---|---|---|
| Male patients with nmCRPC or mHSPC | Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator. Receives: Drug: Darolutamide (Nubeqa, BAY1841788) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number, severity of adverse events (including SAEs)
SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Measured: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Number, severity of adverse drug reactions (including SADRs)
SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.
Measured: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse events
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Measured: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse drug reactions
An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.
Measured: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Secondary outcomes (14)
Metastasis-free survival (MFS) by nmCRPC indication
MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis.
Measured: Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.
Measured: Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.
Measured: Up to 52 weeks
Overall survival by nmCRPC indication
Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.
Measured: Up to 52 weeks
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first.
Measured: Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by mHSPC indication
Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.
Measured: Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by mHSPC indication
Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.
Measured: Up to 52 weeks
Overall survival by mHSPC indication
Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.
Measured: Up to 52 weeks
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
Time to initiation of subsequent anti-cancer therapy is defined as the time (months) from the initiation of Darolutamide treatment to the date of first administration of any subsequent anti-cancer therapy after discontinuation of Darolutamide.
Measured: Up to 52 weeks
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
Radiological progression is defined as the time (months) from the start of Darolutamide treatment to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first.
Measured: Up to 52 weeks
Radiological Progression-Free Survival (rPFS) by mHSPC indication
Radiographic Progression-Free Survival (rPFS) is defined as the time (months) from the initiation of Darolutamide treatment to the date of the first radiologically confirmed disease progression or death from any cause, whichever occurs first.
Measured: Up to 52 weeks
Duration of Darolutamide treatment
Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death).
Measured: Up to 52 weeks
Reasons for ending Darolutamide
Measured: Up to 52 weeks
Dosage and dose modification of Darolutamide
Measured: Up to 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2024
- Study start25 Sep 2024
- Primary completion31 Mar 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-metastatic Castration-resistant Prostate CancerStudies of the same condition, open and under way.
- More trials run by BayerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bayer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06334120
- Sponsor's protocol ID
- 20654
- Status last verified
- 4 Nov 2026
- First submitted
- 21 Mar 2024
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
- ClinicalTrials.gov ID
- NCT06334120
- Acronym / sponsor ID
- 20654
- Conditions
- Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- BayerIndustry (pharma, biotech, devices)
- Study start
- 25 Sep 2024 (actual)
- Primary completion
- 31 Mar 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 27 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.
This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.
To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.
During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.
Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Male patients with nmCRPC or mHSPC | – | Drug: Darolutamide (Nubeqa, BAY1841788)Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator. |
Who may qualify
- Ages
- 19 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.
Key inclusion criteria (9 listed)
- Male aged ≥19 years
- Patients with high risk nmCPRC
- Patients with mHSPC
- Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice
- Written informed consent from subject or legal representative; assent from subject when appropriate
Key exclusion criteria (2 listed)
- Patients participating in an investigational program with interventions outside of routine clinical practice
- Participants with contraindication according to the locally approved prescribing information
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Darolutamide (Nubeqa, BAY1841788)The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information. | Drug | Male patients with nmCRPC or mHSPC |
Primary outcome
Number, severity of adverse events (including SAEs)
Time frame: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Number, severity of adverse drug reactions (including SADRs)
Time frame: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.
The outcome of (serious) adverse events
Time frame: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
The outcome of (serious) adverse drug reactions
Time frame: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.
14 secondary outcomes
Metastasis-free survival (MFS) by nmCRPC indication
Time frame: Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
Time frame: Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
Time frame: Up to 52 weeks
Overall survival by nmCRPC indication
Time frame: Up to 52 weeks
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
Time frame: Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by mHSPC indication
Time frame: Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by mHSPC indication
Time frame: Up to 52 weeks
Overall survival by mHSPC indication
Time frame: Up to 52 weeks
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
Time frame: Up to 52 weeks
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
Time frame: Up to 52 weeks
Radiological Progression-Free Survival (rPFS) by mHSPC indication
Time frame: Up to 52 weeks
Duration of Darolutamide treatment
Time frame: Up to 52 weeks
Reasons for ending Darolutamide
Time frame: Up to 52 weeks
Dosage and dose modification of Darolutamide
Time frame: Up to 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: No. Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Related trials for Non-metastatic Castration-resistant Prostate Cancer
RecruitingPhase 4
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Non-metastatic Castration-resistant Prostate Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationPhase 1
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer
RecruitingPhase 1
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
RecruitingObservational study
Pluvicto Real-world Investigation in Survival in Metastatic CRPC
Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-metastatic Castration-resistant Prostate Cancer and Metastatic Hormone-sensitive Prostate Cancer, run by Bayer at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bayer Clinical Trials Contact (0018888422937, clinical-trials-contact@bayer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number, severity of adverse events (including SAEs) (time frame: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.